AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 14,281 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 14,281 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $638,503.51. Following the completion of the transaction, the chief executive officer owned 479,344 shares of the company’s stock, valued at $21,431,470.24. This represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total value of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $44.67 on Friday. The business’s fifty day moving average is $42.62 and its 200 day moving average is $31.46. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $52.47.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. Equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase plan on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ANAB. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Truist Financial boosted their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Barclays lowered their price target on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $50.00 target price on shares of AnaptysBio in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus target price of $60.40.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Hedge Funds Weigh In On AnaptysBio

Several institutional investors have recently modified their holdings of ANAB. SG Americas Securities LLC purchased a new position in shares of AnaptysBio during the 4th quarter valued at about $506,000. Tudor Investment Corp ET AL grew its position in AnaptysBio by 47.2% during the third quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock valued at $425,000 after acquiring an additional 4,450 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of AnaptysBio by 2.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock worth $11,588,000 after acquiring an additional 10,005 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of AnaptysBio during the third quarter worth approximately $315,000. Finally, Larson Financial Group LLC lifted its holdings in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.